Tekla Healthcare Investors (HQH)
NYSE NYSE Primary NASDAQ (NMS) 
Bargain Alert: 2 Big Dividends, Up To 10% Yield
Immunize your retirement from market noise with recurring dividends. We discuss two essential sectors for reliable income generation, regardless of economic conditions. Discover our top picks with up to 10% yields.
I Am Loading Up Big Dividends For My Golden Years
Innovation, demand, and shortage of providers have kept healthcare inflation significantly higher than the CPI. Regardless of the political scene, the aging U.S. population and rising chronic illnesses are undeniable truths to face. Income investing ensures consistent returns, allowing flexibility in financial planning, despite volatile stock prices.
HQH: Improved Fundamentals, Strong Dividend Support
HQH offers a high dividend yield of 13.6%, making it attractive for income-focused investors, despite potential tax consequences. The fund trades at a 7.86% discount to NAV, presenting a good entry point, especially with anticipated interest rate cuts and increased healthcare spending. HQH's portfolio is heavily concentrated in Biotechnology (64.6%), posing sector-specific risks but also benefiting from projected growth in biotech and healthcare spending.
Don't Miss The Dividend Train, Yields Up To 15%
For over 400 years, dividends have been a steady form of capital from the markets to your account. Dividends can generate dependable and powerful paychecks. We discuss two big yields from dependable sectors.
HQH: Not For Income Investors
I maintain a sell rating on the abrdn Healthcare Investors fund due to its incongruence with income investing and managed distribution plans. HQH has underperformed the Nasdaq Biotechnology Index and iShares Biotechnology ETF, highlighting its inability to generate alpha versus more tax-efficient alternatives. The fund's high yield is unsustainable, relying on capital gains and potentially forcing premature sales, which is unsuitable for income-oriented investors.
HQH: Declines Bring Potential Opportunity
HQH has seen pressure recently due to regulatory uncertainty; while the closed-end funds discount has actually narrowed, it could be an interesting place to put some capital to work. The fund's 12% managed distribution policy has attracted interest from yield investors, though a quarterly pay may be less appealing. HQH's portfolio is tilted toward a heavier weight in biotech, with top holdings like Gilead Sciences showing resilience while others like Regeneron and Eli Lilly have struggled.
HQH: High Yielding Exposure To Biotech With Positive Outlook
abrdn Healthcare Investors operates as a closed end fund that aims to provide total returns comprised of high current income. HQH offers a high-yielding dividend rate of 12.7% and distributions are paid out on a monthly basis. The fund's focus on biotech holdings makes it vulnerable to interest rate changes but also positions it for potential growth with lower rates.
HQH: Discount Remains Attractive With A Now Higher Distribution Rate
The healthcare sector is traditionally defensive during economic downturns, but not all industries within the healthcare sector are created equal. abrdn Healthcare Investors Fund focuses on the more cyclical biotech space, with over half of its portfolio allocated there. HQH's managed distribution policy was increased significantly since our prior update, which was a factor in the funds discount narrowing, but it continues to trade at an attractive discount.
HQH: Double-Digit Discount And Dividend Ready For Biotech Rally
HQH features a deep NAV discount at 11%, it is cheap and offers good opportunity for price appreciation. Biotech sector is showing strength in recent market rally. HQH with high yield at 13% is a good buy for income investors to participate the promising biotech rally. Record financing activities in the sector fuel the business growth and set up for a sustainable market recovery.
Make Money While You Sleep, 2 Big Dividends For A Retirement Dream
What is your dream retirement? Make goals to achieve it. Don't make monetary number goals that can't answer the "what then?" question. I meet expenses head-on with highly valuable income.
abrdn U.S. Closed-End Funds Announce Results of Annual Meeting of Shareholders
PHILADELPHIA, PA / ACCESSWIRE / June 26, 2024 / The following abrdn U.S. Closed-End Funds (NYSE:HQH)(NYSE:THQ)(NYSE:THW) announced they each held their Annual Meeting of Shareholders (the "Meetings") on June 25, 2024. At the Meetings, shareholders of the respective Funds voted on the proposals set forth below: abrdn Healthcare Investors ("HQH") As of the record date, April 1, 2024, HQH had outstanding 50,624,847 shares of common stock.
2 Magnificent Funds To Generate Passive Income
$7.1 trillion is invested in passive ETFs, rocking the market with their inflows and outflows. Few passive ETFs help you achieve specific goals. We look for options to meet our income needs for a lifetime.
